View DividendThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsQuantRx Biomedical マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況お知らせ • Aug 25Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical CorporationEffective August 22, 2022, Michael Abrams resigned from his position as a member of the Board of Directors of QuantRx Biomedical Corporation. Mr. Abram’s resignation from the Board of Directors is not due to any disagreement with respect to the Company’s operations, policies, or practices.すべての更新を表示Recent updatesお知らせ • Apr 10QuantRx Biomedical Corporation Common Stock Deleted from OTC EquityQuantRx Biomedical Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC.お知らせ • Aug 25Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical CorporationEffective August 22, 2022, Michael Abrams resigned from his position as a member of the Board of Directors of QuantRx Biomedical Corporation. Mr. Abram’s resignation from the Board of Directors is not due to any disagreement with respect to the Company’s operations, policies, or practices.お知らせ • Aug 17QuantRx Biomedical Corporation announced delayed 10-Q filingOn 08/16/2022, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01QuantRx Biomedical Corporation announced delayed annual 10-K filingOn 03/31/2022, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Apr 03QuantRx Biomedical Corporation announced delayed annual 10-K filingOn 04/01/2021, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 18QuantRx Biomedical Corporation announced delayed 10-Q filingOn 11/17/2020, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Sep 25QuantRx Biomedical Corporation acquired 14.3% stake in FluoroPharma, Inc.QuantRx Biomedical Corporation (QuantRx) signed a definitive agreement to acquire 14.3% stake in FluoroPharma, Inc., for $1.25 million, on April 5, 2007. This acquisition would increase QuantRx’s stake in FluoroPharma, Inc. to 57.7%. Under the investment agreement, QuantRx agreed to purchase, 627,058 shares of common stock of FluoroPharma in consideration of $1.25 million consisting of cash payments aggregating $0.74 million and cancellation in full of two promissory notes issued by FluoroPharma in favor of QuantRx in the aggregate principal amount of $0.51 million. Greenberg Traurig, LLP acted as legal advisor to QuantRx Biomedical and Burns & Levinson LLP acted as legal advisor to FluoroPharma. QuantRx Biomedical Corporation completed the acquisition of 14.3% stake in FluoroPharma, Inc., on April 13, 2007.CEOQuantRx Biomedical CEOがいない、あるいは彼らに関するデータがない。View Ownership企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2025/04/09 20:54終値2025/03/31 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋QuantRx Biomedical Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 25Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical CorporationEffective August 22, 2022, Michael Abrams resigned from his position as a member of the Board of Directors of QuantRx Biomedical Corporation. Mr. Abram’s resignation from the Board of Directors is not due to any disagreement with respect to the Company’s operations, policies, or practices.
お知らせ • Apr 10QuantRx Biomedical Corporation Common Stock Deleted from OTC EquityQuantRx Biomedical Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC.
お知らせ • Aug 25Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical CorporationEffective August 22, 2022, Michael Abrams resigned from his position as a member of the Board of Directors of QuantRx Biomedical Corporation. Mr. Abram’s resignation from the Board of Directors is not due to any disagreement with respect to the Company’s operations, policies, or practices.
お知らせ • Aug 17QuantRx Biomedical Corporation announced delayed 10-Q filingOn 08/16/2022, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01QuantRx Biomedical Corporation announced delayed annual 10-K filingOn 03/31/2022, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Apr 03QuantRx Biomedical Corporation announced delayed annual 10-K filingOn 04/01/2021, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 18QuantRx Biomedical Corporation announced delayed 10-Q filingOn 11/17/2020, QuantRx Biomedical Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Sep 25QuantRx Biomedical Corporation acquired 14.3% stake in FluoroPharma, Inc.QuantRx Biomedical Corporation (QuantRx) signed a definitive agreement to acquire 14.3% stake in FluoroPharma, Inc., for $1.25 million, on April 5, 2007. This acquisition would increase QuantRx’s stake in FluoroPharma, Inc. to 57.7%. Under the investment agreement, QuantRx agreed to purchase, 627,058 shares of common stock of FluoroPharma in consideration of $1.25 million consisting of cash payments aggregating $0.74 million and cancellation in full of two promissory notes issued by FluoroPharma in favor of QuantRx in the aggregate principal amount of $0.51 million. Greenberg Traurig, LLP acted as legal advisor to QuantRx Biomedical and Burns & Levinson LLP acted as legal advisor to FluoroPharma. QuantRx Biomedical Corporation completed the acquisition of 14.3% stake in FluoroPharma, Inc., on April 13, 2007.